Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY
Status:
Unknown status
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Lipodystrophie, peripheral neuropathy and mitochondrial toxicity has been associated to
stavudine at standard doses The aim of this study is to evaluate the efficacy of reduced
doses of stavudine (30 mg b.i.d.) in HIV patients with controlled viral load and body weight
> 60 kg, receiving an antiretroviral therapy containing stavudine 40 mg b.i.d.